5.20

4.84% 0.24

Solid Biosciences Inc (SLDB)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché SLDB Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$4.96

Aprire:

$5.02

Volume 24 ore:

346.67K

Relative Volume:

1.25

Capitalizzazione di mercato:

$198.17M

Reddito:

$14.79M

Utile/perdita netta:

$-102.44M

Rapporto P/E:

-0.8419

EPS:

-6.1766

Flusso di cassa netto:

$-91.73M

1 W Prestazione:

-2.07%

1M Prestazione:

-10.65%

6M Prestazione:

-38.90%

1 anno Prestazione:

+116.67%

Intervallo 1D:

$4.94

$5.38

Intervallo di 1 settimana:

$4.61

$5.515

Portata 52W:

$2.44

$15.05

Solid Biosciences Inc Stock (SLDB) Company Profile

Nome

Solid Biosciences Inc

Settore

Healthcare (1195)

Industria

Biotechnology (683)

Telefono

617-337-4680

Indirizzo

500 RUTHERFORD AVENUE, CHARLESTOWN, MA

Dipendente

Cinguettio

@SolidBioDMD

Prossima data di guadagno

2024-11-06

Ultimi documenti SEC

SLDB's Discussions on Twitter

Confronta SLDB con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
SLDB	5.20	198.17M	14.79M	-102.44M	-91.73M	-6.1766
VRTX	449.99	115.43B	10.63B	-479.80M	-1.35B	13.33
REGN	747.10	82.04B	13.85B	4.65B	3.32B	35.06
ARGX	591.88	35.30B	1.86B	-40.29M	-1.28B	-4.16
ALNY	246.13	32.04B	2.09B	-332.26M	16.06M	-4.14
BNTX	107.68	24.89B	3.30B	-501.07M	1.03B	11.54

Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-07-15	Aggiornamento	JP Morgan	Neutral → Overweight
2024-06-24	Aggiornamento	Leerink Partners	Market Perform → Outperform
2024-05-31	Ripresa	Piper Sandler	Overweight
2024-03-28	Iniziato	William Blair	Outperform
2024-03-15	Iniziato	Citigroup	Buy
2024-03-14	Aggiornamento	Piper Sandler	Neutral → Overweight
2023-12-08	Iniziato	H.C. Wainwright	Buy
2021-07-12	Iniziato	Piper Sandler	Neutral
2021-05-27	Iniziato	Jefferies	Buy
2021-03-16	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2021-03-09	Iniziato	Barclays	Overweight
2021-01-08	Aggiornamento	Credit Suisse	Underperform → Neutral
2020-07-28	Downgrade	SVB Leerink	Outperform → Mkt Perform
2020-05-07	Downgrade	Evercore ISI	Outperform → In-line
2019-10-11	Iniziato	Evercore ISI	Outperform
2019-08-29	Downgrade	Citigroup	Neutral → Sell
2019-08-19	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2019-08-16	Aggiornamento	Chardan Capital Markets	Neutral → Buy
2019-05-14	Downgrade	Credit Suisse	Neutral → Underperform
2019-05-14	Downgrade	Goldman	Neutral → Sell
2019-02-08	Aggiornamento	Citigroup	Sell → Neutral
2019-02-08	Downgrade	SVB Leerink	Outperform → Mkt Perform
2018-11-06	Iniziato	Citigroup	Sell
2018-09-06	Iniziato	Credit Suisse	Neutral

Mostra tutto

Solid Biosciences Inc Borsa (SLDB) Ultime notizie

07:09 AM

Is Solid Biosciences (NASDAQ:SLDB) In A Good Position To Invest In Growth? - Simply Wall St

Nov 16, 2024

Nov 15, 2024

Perceptive Advisors LLC's Strategic Acquisition in Solid Bioscie - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Vestal Point Capital, LP Increases Stake in Solid Biosciences Inc. - GuruFocus.com

Nov 14, 2024

FY2024 Earnings Estimate for SLDB Issued By Chardan Capital - MarketBeat

Nov 14, 2024

Solid Biosciences to Present at the Jefferies London Healthcare Conference - GlobeNewswire

Nov 14, 2024

Solid Biosciences CEO to Present at Jefferies London Healthcare Conference | SLDB Stock News - StockTitan

Nov 14, 2024

Nov 13, 2024

Solid Biosciences' SWOT analysis: DMD therapy stock faces pivotal moment - Investing.com India

Nov 13, 2024

Solid Biosciences' SWOT analysis: DMD therapy stock faces pivotal moment By Investing.com - Investing.com UK

Nov 13, 2024

Nov 12, 2024

JPMorgan Chase & Co. Lowers Solid Biosciences (NASDAQ:SLDB) Price Target to $12.00 - MarketBeat

Nov 12, 2024

Nov 11, 2024

HC Wainwright Analysts Decrease Earnings Estimates for SLDB - MarketBeat

Nov 11, 2024

Research Analysts Issue Forecasts for SLDB FY2024 Earnings - MarketBeat

Nov 11, 2024

Nov 09, 2024

We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate - Yahoo Finance

Nov 09, 2024

Nov 08, 2024

Solid Biosciences Inc. (NASDAQ:SLDB) Receives $15.67 Consensus Target Price from Brokerages - MarketBeat

Nov 08, 2024

Nov 07, 2024

Solid Biosciences (NASDAQ:SLDB) Given Buy Rating at HC Wainwright - MarketBeat

Nov 07, 2024

Nov 06, 2024

Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates - The Manila Times

Nov 06, 2024

Solid Biosciences: SGT-003 Trial Shows Promise, $171M Cash Runway Despite Wider Q3 Loss | SLDB Stock News - StockTitan

Nov 06, 2024

Senhwa Biosciences announces first patient dosed in the Phase I/II study of Silmitasertib in children and young adults with relapsed refractory solid tumors. - PR Newswire

Nov 06, 2024

Where are the Opportunities in (SLDB) - Stock Traders Daily

Nov 06, 2024

Nov 04, 2024

Exosome Therapies on the Rise as 70+ Major Companies Driving Development in the Field | DelveInsight - The Malaysian Reserve

Nov 04, 2024

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 04, 2024

Nov 02, 2024

Millennium Management LLC Reduces Stake in Solid Biosciences Inc - GuruFocus.com

Nov 02, 2024

Oct 31, 2024

Sow Good to Hold Third Quarter 2024 Conference Call on Thursday, November 14, 2024 at 10:00 a.m. ET - The Manila Times

Oct 31, 2024

Solid Biosciences to Participate at the Truist Securities BioPharma Symposium - GlobeNewswire

Oct 31, 2024

Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace

Oct 31, 2024

Oct 29, 2024

Global Exosome Market to Surge at a Tremendous CAGR of ~20% by 2030 | DelveInsight - GlobeNewswire

Oct 29, 2024

Duchenne Muscular Dystrophy Therapeutics Market Trends, Growth Insights, and Forecasts 2033 - WhaTech

Oct 29, 2024

Oct 28, 2024

WRN inhibitor IDE-275 gains IND clearance for phase I study in MSI-high tumors - BioWorld Online

Oct 28, 2024

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors - BioSpace

Oct 28, 2024

Oct 26, 2024

(SLDB) Proactive Strategies - Stock Traders Daily

Oct 26, 2024

Oct 24, 2024

Pillar Biosciences Receives CPT® Code for FDA Approved oncoReveal™ CDx Pan-Cancer Solid tumor IVD Kit - PR Newswire

Oct 24, 2024

Oct 22, 2024

Solid Biosciences CMO sells $18,999 in stock - Investing.com India

Oct 22, 2024

Solid Biosciences CMO sells $18,999 in stock By Investing.com - Investing.com Canada

Oct 22, 2024

Insider Selling: Solid Biosciences Inc. (NASDAQ:SLDB) Insider Sells 2,923 Shares of Stock - MarketBeat

Oct 22, 2024

Oct 16, 2024

Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences - Quantisnow

Oct 16, 2024

Seraxis gains IND clearance for islet replacement therapy - BioWorld Online

Oct 16, 2024

Oct 15, 2024

(SLDB) Trading Signals - Stock Traders Daily

Oct 15, 2024

Oct 14, 2024